Vigabatrin: clinical evidence supporting rational polytherapy in management of uncontrolled seizures.
Monotherapy is the policy for management of patients with epilepsy. With increasing knowledge of the biology of epilepsy and of the modes of action of antiepileptic drugs (AEDs), this concept must be reevaluated. When monotherapy fails to control seizures, subsequent treatment should be based on "rational pharmacology," taking into consideration the mode of action of the drugs, to provide improved efficacy with maintained tolerance and ease of administration. Introduction of vigabatrin (VGB) as a new AED calls for just such a reevaluation. VGB is an enzyme-activated irreversible inhibitor of gamma-aminobutyric acid (GABA)-transaminase that increases brain and cerebrospinal (CSF) GABA concentrations in animals and humans. It has limited efficacy in the classic animal seizure screening tests, but in many clinical studies has halved the incidence of seizures in approximately 50% of patients, especially those with partial epilepsies. We evaluated the efficacy of VGB in "socially integrated and active outpatients" as a likely subset to demonstrate any advantage of rational polytherapy. The criteria for this evaluation included the effects on seizure frequency, patient tolerability, and cognitive performance in a battery of psychometric tests. Fourteen of the 19 patients (73%) completing the study had > 50% reduction in seizure frequency, and 10 of 19 (52%) had > 70% reduction in seizure frequency. Tolerability appeared good; somnolence was the most frequent adverse event. Three patients complained of a worsening of their seizures, 1 with an increase in frequency and 2 with development of myoclonic jerks not previously reported.(ABSTRACT TRUNCATED AT 250 WORDS)
de Bittencourt
P R
PR
Clinical Neurology Unit, Hospital Nossa Senhora das Graças, Curitiba, Brazil.
Mazer
S
S
Marcourakis
T
T
Bigarella
M M
MM
Ferreira
Z S
ZS
Mumford
J P
JP
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000614:Aminocaproates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D011939:Mental Recall / Q000187:drug effects; D008875:Middle Aged; D010919:Placebos; D011581:Psychological Tests; D012720:Severity of Illness Index; D016037:Single-Blind Method; D012890:Sleep / Q000187:drug effects; D016896:Treatment Outcome; D020888:Vigabatrin
D000614:Aminocaproates; D000927:Anticonvulsants; D010919:Placebos; D020888:Vigabatrin